Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

CicloMed expands clinical trial for bladder cancer drug

By Chris Newmarker | December 4, 2019

CicloMedCicloMed (Kansas City, Mo.) has expanded the Phase 1 clinical trial for fosciclopirox, its bladder cancer drug candidate.

The trial has been expanded to include patients with muscle-invasive bladder cancer who are ineligible to receive cisplatin chemotherapy, the company said yesterday. Researchers have enrolled the first patient at The University of Kansas Cancer Center; the study extension is expected to be completed within 12 months.

The study extension comes after completion of a first-in-human Phase 1 dose-escalation study in 19 advanced solid-tumor patients. The study gathered safety, dose tolerance, pharmacokinetic and pharmacodynamics data resulting in the identification of the fosciclopirox recommended Phase 2 dose.

“We are excited to launch this expansion cohort study to begin evaluating the antitumor activity of fosciclopirox in a well-defined subgroup of bladder cancer patients,” Tammy Ham, president and CEO of CicloMed, said in a news release.

“As a National Cancer Institute (NCI)-designated center, the KU Cancer Center is a strong partner in providing scientific and clinical expertise to support CicloMed’s fosciclopirox drug development program,” Ham said.

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

COVID-19
NIH halts COVID-19 convalescent plasma trial
Johnson & Johnson Merck COVID-19 vaccine
Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
Data
The COVID-19 effect: Research platforms require new capabilities
COVID-19 vaccine
Is there a link between Bell’s palsy and COVID-19 vaccines?

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards